Pulsenmore Ltd. has announced the appointment of David Woods as its new Chief Commercial Officer (CCO) as part of a strategic initiative to enhance its U.S. operations. This move is significant for the company as it aims to capitalize on the increasing demand for accessible prenatal care and the opportunities presented by federal investments in rural health.
Founded in Israel, Pulsenmore Ltd. operates in the surgical and medical instruments sector (SIC 3841). The company trades on the Nasdaq under the ticker PLSM. Its recent filings include a series of 6-K reports, with the latest submitted on October 13, 2026, detailing this important leadership change.
According to the filing, Pulsenmore's press release states, "Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer." This appointment is part of an effort to expand the company’s commercial team and accelerate its growth in the U.S. healthcare market.
David Woods brings over 25 years of experience in the medical technology field, having previously served as CCO at Creo Medical and held senior roles at PENTAX Medical. His extensive background is expected to bolster Pulsenmore's efforts to penetrate the U.S. market, particularly following the FDA's De Novo authorization of its home prenatal ultrasound system.
The company’s technology allows pregnant women to perform ultrasound scans at home, with remote interpretation by healthcare providers. This innovation aims to extend prenatal monitoring beyond traditional healthcare settings, addressing significant gaps in maternal care access, especially in rural and underserved communities.
Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore, expressed optimism about the U.S. market, stating, "We believe the U.S. market presents a significant opportunity for Pulsenmore, with growing recognition of the need to bring maternal care closer to patients." The expansion of the commercial team and the hiring of Woods reflect the company's commitment to translating market opportunities into sustainable growth.
Woods also shared his enthusiasm about joining Pulsenmore, emphasizing the potential impact of bringing ultrasound technology into the home for improving maternal healthcare access. He stated, "I look forward to contributing my experience to help expand that impact." This leadership change is expected to influence not only Pulsenmore but also the broader medical instruments industry as companies adapt to changing healthcare demands.
As Pulsenmore continues to explore opportunities associated with the U.S. federal Rural Health Transformation Program, it aims to enhance access to maternal health services and technology-enabled care. The company’s proactive approach in expanding its leadership and commercial capabilities underscores a growing trend in the industry towards innovative solutions that prioritize patient accessibility and care.
Details were not available in the SEC filing regarding the next steps following this appointment, but it is clear that Pulsenmore is poised to make significant strides in the U.S. healthcare market under Woods' leadership.